Overview

A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and clinical activity of GEN1042 in combination with radiotherapy with or without pembrolizumab as a treatment option for patients with metastatic solid tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genmab

Collaborator:

BioNTech SE

Treatments:

Pembrolizumab